Recent Company News

• 04:28 AM ET Jul 01, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:56 AM ET Jul 01, 2026
  

  StreetAccount Summary - European pre-market trading update

• 02:44 AM ET Jul 01, 2026
  

  Lonza Group expands long-term biopharma partnership with multi-billion CHF potential (CHF 545.80, 0.00)

• 12:43 AM ET Jun 23, 2026
  

  Lonza Group reports restated 1H25 financials reflecting Capsules & Health Ingredients as discontinued operations (CHF 500.40, 0.00)

• 12:02 AM ET Jun 23, 2026
  

  Trading halted in Lonza Group pending news (CHF 500.40, 0.00)

• 01:46 PM ET Jun 15, 2026
  

  Lonza issues exclusive, target-specific license to Antharis Therapeutics to advance dual payload ADCs for gastrointestinal cancers (CHF 495.00, 0.00)

• 02:01 PM ET May 11, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 4-May

• 12:39 AM ET May 08, 2026
  

  Lonza qualitative Q1 business update: strong performance across CDMO business (CHF 486.20, 0.00)

• 11:09 AM ET May 01, 2026
  

  US FTC grants antitrust clearance for Lone Star Funds' purchase of Lonza Group's Capsules & Health Ingredients business (CHF 479.20, 0.00)

• 07:57 AM ET Apr 21, 2026
  

  Simulations Plus announces funded research collaboration with Lonza Group and FDA to advance predictive frameworks for complex oral drug products ($14.97, 0.00)